We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Recommends Approval of BMS’s Daklinza for Chronic Hepatitis C
EMA Recommends Approval of BMS’s Daklinza for Chronic Hepatitis C
A European Medicines Agency committee has recommended approval of Bristol-Myers Squibb’s direct-acting antiviral Daklinza in combination with other drugs for the treatment of chronic hepatitis C virus (HCV) infection in adults.